<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574649</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-2.024</org_study_id>
    <nct_id>NCT03574649</nct_id>
  </id_info>
  <brief_title>QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer</brief_title>
  <official_title>QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and&#xD;
      adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard&#xD;
      of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa&#xD;
      resectable NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial not initiated&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival ( RFS)</measure>
    <time_frame>18 months</time_frame>
    <description>time from the date of randomization to the date of first radiographically determined new lesion by RECIST Version 1.1 based on BICR or date of death (by any cause), whichever occurs first</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>(SP-4-2)-diamminedichloroplatinum(II)</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury vaccine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>RAS yeast vaccine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast vaccine</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldoxorubicin</intervention_name>
    <description>INNO-206</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Fully human anti-PD-L1 IgG1 lambda monoclonal antibody</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)</description>
    <arm_group_label>NANT NSCLC Combination Immunotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or IEC guidelines.&#xD;
&#xD;
          3. Histologically-confirmed stage II-IIIa NSCLC.&#xD;
&#xD;
          4. ECOG performance status of 0 to 2.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of &gt; 1.0 cm.&#xD;
&#xD;
          6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most&#xD;
             recent anticancer treatment and be willing to release the specimen for prospective and&#xD;
             exploratory tumor molecular profiling. If an historic specimen is not available, the&#xD;
             subject must be willing to undergo a biopsy during the screening period, if considered&#xD;
             safe by the Investigator. If safety concerns preclude collection of a biopsy during&#xD;
             the screening period, a tumor biopsy specimen collected prior to the conclusion of the&#xD;
             most recent anticancer treatment may be used.&#xD;
&#xD;
          7. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for prospective tumor molecular profiling and exploratory analyses.&#xD;
&#xD;
          8. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          9. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment. Effective contraception includes surgical sterilization (eg, vasectomy,&#xD;
             tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with&#xD;
             spermicide, intrauterine devices (IUDs), and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          3. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          5. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1,000 cells/mm3.&#xD;
&#xD;
               2. Uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL).&#xD;
&#xD;
               3. Platelet count &lt; 75,000 cells/mm3.&#xD;
&#xD;
               4. Total bilirubin greater than the ULN; unless the subject has documented Gilbert's&#xD;
                  syndrome).&#xD;
&#xD;
               5. AST (SGOT) or ALT (SGPT) &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases).&#xD;
&#xD;
               6. ALP levels &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases, or &gt;10 × ULN&#xD;
                  in subjects with bone metastases).&#xD;
&#xD;
               7. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               8. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with&#xD;
             uncontrolled hypertension should be medically managed on a stable regimen to control&#xD;
             hypertension prior to study entry.&#xD;
&#xD;
          7. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the&#xD;
             institution's lower limit of predicted normal.&#xD;
&#xD;
          8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
          9. Positive results of screening test for HIV.&#xD;
&#xD;
         10. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         11. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         15. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 30 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         16. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         17. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         18. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

